- Home
- FGEN vs MAIA Comparison
FGEN vs MAIA Comparison
Compare FGEN & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- MAIA
- Stock Information
- Founded
- FGEN 1993
- MAIA 2018
- Country
- FGEN United States
- MAIA United States
- Employees
- FGEN N/A
- MAIA N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- MAIA Health Care
- Exchange
- FGEN Nasdaq
- MAIA Nasdaq
- Market Cap
- FGEN 45.1M
- MAIA 44.9M
- IPO Year
- FGEN 2014
- MAIA 2022
- Fundamental
- Price
- FGEN $8.66
- MAIA $1.00
- Analyst Decision
- FGEN Strong Buy
- MAIA
- Analyst Count
- FGEN 2
- MAIA 0
- Target Price
- FGEN $146.50
- MAIA N/A
- AVG Volume (30 Days)
- FGEN 31.2K
- MAIA 689.4K
- Earning Date
- FGEN 11-10-2025
- MAIA 11-07-2025
- Dividend Yield
- FGEN N/A
- MAIA N/A
- EPS Growth
- FGEN N/A
- MAIA N/A
- EPS
- FGEN 53.38
- MAIA N/A
- Revenue
- FGEN $8,298,000.00
- MAIA N/A
- Revenue This Year
- FGEN N/A
- MAIA N/A
- Revenue Next Year
- FGEN N/A
- MAIA N/A
- P/E Ratio
- FGEN $0.16
- MAIA N/A
- Revenue Growth
- FGEN N/A
- MAIA N/A
- 52 Week Low
- FGEN $4.85
- MAIA $0.98
- 52 Week High
- FGEN $21.94
- MAIA $2.74
- Technical
- Relative Strength Index (RSI)
- FGEN 25.08
- MAIA 31.42
- Support Level
- FGEN $8.30
- MAIA $0.98
- Resistance Level
- FGEN $11.39
- MAIA $1.16
- Average True Range (ATR)
- FGEN 0.51
- MAIA 0.09
- MACD
- FGEN -0.26
- MAIA -0.01
- Stochastic Oscillator
- FGEN 12.95
- MAIA 2.23
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.